1. Antiviral Drugs That Are Approved, Authorized, or Under Evaluation for the Treatment of COVID-19 [Review of Antiviral Drugs That Are Approved, Authorized, or Under Evaluation for the Treatment of COVID-19]. (2022, September 26). NIH.GOV; National Institute for Health.
2. Beigel JH, et al. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med. 2020;383(19):1813.
3. Brusamolino E, Gotti M, Fiaccadori V. The risk of therapy-related myelodysplasia/acute myeloid leukemia in Hodgkin lymphoma has substantially decreased in the ABVD era A-abolishing mechlorethamine and procarbazine and limiting volumes and doses of radiotherapy. In: Medical Journal of Hematology and Infectious Diseases, 4. Open Journal: System; 2012.
4. Karolyn M, et al. Early administration of remdesivir may reduce mortality in hospitalized Covid-19 patients. Cent Eur J Med. 2022; https://doi.org/10.1007/s00508-022-02098-9.
5. Nygaard M, Wichert S, Toss F. Extracorporeal photopheresis for graft versus host disease: a literature review and treatment guidelines proposed by the Nordic ECP Quality Group. Eur J Haematol. 2020;104(5):361.